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At the end of 2013, The United Nations (UN) GeneralAssembly 68th Session proclaimed 2015 to be the In-
ternational Year of Light (IYL). Various scientific orga-
nizations, institutions, and societies are to all be brought
together to raise global awareness about light (and lasers) and
its uses in technology, including medicine, and everyday use.
This worldwide program will highlight our dependence on
light, and its importance to our lives. John Dudley, Chairman
of the IYL 2015 Steering Committee stated that ‘‘An Inter-
national Year of Light is a tremendous opportunity to ensure
that international policymakers and stakeholders are made
aware of the problem-solving potential of light technology.
We now have a unique opportunity to raise global awareness
of this.’’1 The IYL has given us all a unique opportunity to
showcase our research and the importance and usefulness of
light in medicine.
Since the development of the first laser, the use of lasers
and light in medicine has made great strides; new technologies
have since been developed and continue to advance. Today,
photomedicine is practiced in a wide variety of fields, in-
cluding but not limited to ophthalmology, dermatology, den-
tistry, veterinary science, somatology, regenerative medicine,
physiotherapy, surgery, and oncology. One area of research
that has been receiving much attention is the use of light [both
lasers and light emitting diodes (LED)] in improving and
speeding up wound healing. A wound is a pathological state in
which tissue integrity has been lost. Wound healing is an
intricate process aimed at reversing the loss of this tissue
integrity, and is directed toward closure of the defect, usually
by replacement with scar-forming connective tissue, and is
highly coordinated and controlled at the wound site. If there is
a delay or disruption to this process, delayed wound healing
ensues; a complication that is frequently seen in diabetes.
As defined by the International Diabetes Federation
(IDF), diabetes mellitus (DM) is a chronic disease that oc-
curs as a result of the pancreas failing to make insulin. or
when the body can no longer make use of the insulin that is
produced.2 DM is a threat to global development and has
been declared as a global burden, with 382,000,000 cases
worldwide in 2013.3 Because of the damage inflicted on the
blood vessels (angiopathy) and nerves (neuropathy), dia-
betic patients often experience sensory loss in the lower
extremities, and as a result, small sores go unnoticed and
develop into non-healing chronic ulcers. The ulcer recur-
rence rate over 5 years is as high as 70%, and these ulcers
often require amputation.4 Diabetic foot ulcers are one of
the most costly complications of the disease, accounting for
50% of all nontraumatic amputations.5 Diabetic foot ulcers
require extensive long-term treatment by clinicians, and
they impact heavily on the quality of life of the patient,
comparable with that of a patient with breast cancer.6 The
treatment of diabetic foot ulcers includes wound dressing,
debridement, off-loading, corrective shoe wear, infection
control, and surgery. New advances in the treatment of di-
abetic foot ulcers have been developed, such as hyperbaric
oxygen therapy (HBOT), and dressings that have growth
factors incorporated into them. Advances in the area of
photonics and photobiomodulation have led to the use of
lasers and LEDs in the treatment of diabetic ulcers.
A number of clinical studies in animal models and humans
have shown the beneficial effects of photobiomodulation in
speeding up the healing process in slow-to-heal diabetic foot
ulcers.7–17 There is an increase in wound closure,7,13–15 col-
lagen production,8,9 epithelization, and granulation tissue,11
and a decrease in inflammatory cells and oxidative stress.9 Al-
Watban7 conducted a large study on Sprague–Dawley rats
(n= 893) using various wavelengths at 532 (20.4mW/cm2),
633 (15.56mW/cm2), 810 (22.22mW/cm2), 980 (22.22mW/
cm2), and 10,600nm (66.37mW/cm2), as well as LED clus-
ters (510–872nm, 13.6mW/cm2). A full-thickness wound or
burn was created and treated three times a week at incident
doses of 5, 10, 20, and 30 J/cm2. The best results were seen
with the 633 nm laser, and it was recommended that a dose
of 4.71 J/cm2, three times per week be used for diabetic burn
wounds, and a dose of 2.35 J/cm2 three times per week be
used for diabetic wounds for human clinical trials.
Another study showed that daily irradiation with a 660 nm
(80mW) diode laser at a dose of 1.6 J/day (3.7–5.0 J/cm2)
for 7 days resulted in healing of splinted wounds in genetic
diabetic mice, and that healing was mainly caused by re-
epithelization and granulation tissue formation.11 Another
study looked at the effect of laser irradiation on oxidative
stress in diabetic rats. Diabetic (streptozotocin) induced
male Wistar rats (n = 42) were wounded with a 3mm punch
biopsy and irradiated at 940 nm at a dose of 10 J/cm2
(0.1W) immediately after surgery and again on days 2, 4,
and 6 post-surgery.9 On day 14, there was a significant
decrease in inflammatory cells and increased collagen syn-
thesis and vascularization in the irradiated group compared
with the unirradiated, control group as determined by
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histology. No significant differences were found in oxidant
and antioxidant status between the groups.9
Minatel and colleagues14 showed that combined LED at
660 and 890 nm (3 J/cm2, 100mW/cm2) applied twice a
week for a maximum of 90 days promoted rapid granulation
of wounds and healing of ulcers in 14 diabetic patients. In a
similar study, 20 diabetic patients with chronic non-healing
ulcers were treated using the same device and protocol.17
Medium- and large-sized ulcers healed significantly faster
with photobiomodulation than placebo-irradiated ulcers or
control ulcers (cleaned and dressed only). In another study
that involved 23 diabetic patients, foot ulcers were treated at
685 nm, (10 J/cm2, 50mW/cm2) six times per week, for 2
successive weeks and then every other day until the ulcers
were healed.15 By the 4th week, ulcers in the treated group
(n = 13) showed a reduction in size compared with the pla-
cebo group (n = 9). The same was seen at the 20th week;
however, these results were not significant.15
A study conducted in India on 68 type 2 diabetic patients
showed a reduction in ulcer size by 40.24% as compared
with 11.87% in the control group.18 The effects of light on
diabetic cells in culture has also been demonstrated and has
shown favorable effects.19–27 Exposure of diabetic cells has
led to increased cellular migration,20–23 proliferation and
viability,20,22–25 collagen production,19 adenosine triphos-
phate (ATP) mitochondria concentration, and cytochrome c
oxidase activity,26 and a decrease in apoptosis and pro-
inflammatory cytokines.20,27
Advances in the area of photonics and photobiomodula-
tion continue to revolutionize and transform our world, and,
more specifically, the medical industry. The advancement of
photobiomodulation is the result not of one individual’s ef-
forts, but of the work of a number of researchers and clini-
cians over the years. If this treatment modality is to become
better recognized for the healing of diabetic ulcers, larger,
well controlled clinical studies with statistically significant
results are required. There is a definite need to generate new
treatment modalities to improve diabetic wound healing, and
photobiomodulation has an unmistakable place in this. It
would be ignorant to emasculate a multidisciplinary ap-
proach, and photobiomodulation needs to be adequately and
critically studied alongside existing treatments in a clinical
environment for its benefits to be properly recognized.
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